Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing

The most questions were asked about issues such as accelerated approval and clinical trials, not Gottlieb's ties to industry.

Scott Gottlieb's industry ties and potential for a conflict of interest generated wide-spread discussion upon his nomination as FDA commissioner, but other topics took center stage during his Senate confirmation hearing.

A Pink Sheet analysis of the 60 asked questions by members of the Senate Health, Education, Labor and Pensions Committee...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership